HomeREGULATORY
REGULATORY

Abilify, Lixiana and Others under PMDA Risk Review
(Dec.12.2017)

The Pharmaceuticals and Medical Devices Agency (PMDA) is reviewing the risk of impulse-control disorder for Otsuka Pharmaceutical’s antipsychotic Abilify (aripiprazole/aripiprazole hydrate) and its generic versions - a move that is likely to result in label changes - according to the agency’s risk communication update on December 11 ...
(LOG IN FOR FULL STORY)

News Calendar